XML 18 R7.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Cash Flows from Operating Activities    
Net loss $ (23,427) $ (21,494)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,088 1,078
Amortization of intangible assets 140 152
Non-cash lease expense 219  
Accretion of discounts and amortization of premiums on marketable securities (353) (213)
Stock-based compensation 3,703 4,924
Loss from remeasurement of fair value of contingent consideration   365
Loss on disposal of property and equipment   4
Deferred income tax (35) (21)
Changes in operating assets and liabilities:    
Accounts receivable 11,330 288
Prepaid expenses and other assets (368) 265
Accounts payable 202 679
Deferred revenue (3,174) (3,644)
Accrued clinical trial and manufacturing expenses 216 (2,075)
Accrued expenses and other liabilities (1,556) (909)
Operating lease liabilities 806  
Net cash used in operating activities (11,209) (20,601)
Cash Flows from Investing Activities    
Purchase of marketable securities (77,790) (121,152)
Proceeds from maturities of marketable securities 76,103 85,749
Purchase of property and equipment (424) (2,119)
Net cash used in investing activities (2,111) (37,522)
Cash Flows from Financing Activities    
Proceeds from exercise of stock options and warrants 251 617
Net cash provided by financing activities 251 617
Effect of exchange rate changes (127) 171
Net decrease in cash, cash equivalents and restricted cash (13,196) (57,335)
Cash, cash equivalents and restricted cash at beginning of period 126,778 158,082
Cash, cash equivalents and restricted cash at end of period 113,582 100,747
Supplemental Disclosure of Non-Cash Investing and Financing Activities    
Purchase of property and equipment in accounts payable and accrued liabilities 41 781
Reconciliation of Cash, Cash Equivalents and Restricted Cash    
Cash and cash equivalents 113,114 100,279
Restricted cash 468 468
Cash, cash equivalents and restricted cash at end of period $ 113,582 $ 100,747